Plus   Neg

Novartis Reports Positive Results From Ofatumumab Phase III Studies

Novartis (NVS) said ofatumumab showed superiority over Aubagio in patients with relapsing forms of multiple sclerosis in Phase III ASCLEPIOS I and II studies. The head-to-head studies met the primary endpoints with ofatumumab showing a clinically meaningful reduction in the number of confirmed relapses. The company expects to begin submissions to health authorities by 2019-end.

Novartis gained rights for ofatumumab from Genmab in all indications in 2015. The company started a Phase III program for ofatumumab in relapsing forms of multiple sclerosis in 2016.

For comments and feedback contact: editorial@rttnews.com

Follow RTT